Cognitive Subscale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A study indicated that crossword fans had better cognitive function in old age, but experts say it’s still a cryptic question

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of low-dose interleukin 2 (ld IL-2) in 8 patients with Alzheimer’s disease (AD). The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.The additional cl...

Last week's FDA approval of the anti-amyloid lecanemab is being hailed by some Alzheimer's experts as a major advance; others are less certain and have concerns about the drug's efficacy, safety, and cost.

The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. Coya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to enhance in vivo the anti-inflammatory function of regulatory T cells (Tregs). Treg dysfunction has been associated with increased neuroinflammation, which is observe...

FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug's clinical benefit for patients with Alzheimer's disease.